Skip to main
PHGE

BiomX Inc. (PHGE) Stock Forecast & Price Target

BiomX Inc. (PHGE) Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

BiomX Inc. demonstrates a strong positive outlook due to favorable clinical trends evidenced by its BX211 candidate, which shows improvement in key parameters such as infection resolution and reductions in C-Reactive Protein levels among patients with diabetic foot osteomyelitis. The company's recent advancements, including FDA support for its BX011 multi-phage cocktail moving into Phase 2a trials, further bolster its prospects, as these trials target multiple efficacy endpoints and aim to enhance lung function and quality of life for cystic fibrosis patients. Additionally, BiomX's strategic plans for market penetration, expansion of indications based on clinical data, and broader valuations that include ex-U.S. markets suggest significant commercial potential and a clear regulatory trajectory moving forward.

Bears say

BiomX Inc. is experiencing negative investor sentiment due to the marginal results from its clinical trials, specifically the p-values for key endpoints which narrowly missed conventional thresholds for statistical significance. The company's potential for future growth is further constrained by risks associated with failed or inconclusive clinical trials, challenges in securing adequate funding for drug development, and the threat of dilutive capital raises impacting shareholder value. Additionally, the lack of commercial success in delivering effective treatments adds to the negative outlook for BiomX's stock performance.

BiomX Inc. (PHGE) has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of BiomX Inc. and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About BiomX Inc. (PHGE) Forecast

Analysts have given BiomX Inc. (PHGE) a Strong Buy based on their latest research and market trends.

According to 1 analysts, BiomX Inc. (PHGE) has a Strong Buy consensus rating as of Jan 1, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $26, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $26, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

BiomX Inc. (PHGE)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.